Inhibition of endotoxin response by E5564, a novel toll-like receptor 4-directed endotoxin antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 3, 2003, Pages 1093-1102

  Mullarkey, Maureen ^a   Rose, Jeffrey R ^a   Bristol, John ^a   Kawata, Tsutomu ^b   Kimura, Akufumi ^b   Kobayashi, Seiichi ^a   Przetak, Melinda ^a   Chow, Jesse ^a   Gusovsky, Fabian ^a   Christ, William J ^a,c   Rossignol, Daniel P ^d  

^a EISAI RESEARCH INSTITUTE   (United States)

^b EISAI CO LTD   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

^d EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEXTRO GLUCOPYRANOSE 3 O DECYL 2 DEOXY 6 O [2 DEOXY 3 O (3 METHOXYDECYL) 6 O METHYL 2 [(1 OXO 11 OCTADECENYL)AMINO] 4 O PHOSPHONO BETA DEXTRO GLUCOPYRANOSYL] 2 [(1,3 DIOXOTETRADECYL)AMINO] DIHYDROGEN PHOSPHATE; CYTOKINE; DISACCHARIDE; E 5531; E 5564; ENDOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BACTERIAL MEMBRANE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE TIME EFFECT RELATION; DRUG POTENCY; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN CELL; LETHALITY; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; DROSOPHILA PROTEINS; DRUG INTERACTIONS; ENDOTOXINS; ESCHERICHIA COLI; GUINEA PIGS; HUMANS; LIPID A; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MONOCYTES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE; SHOCK, SEPTIC; TIME FACTORS; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037372661     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.044487     Document Type: Article

References (40)

1. Bone RC (1991a) A critical evaluation of new agents for the treatment of sepsis. J Am Med Assoc 266:1686-1691.
2. Bone RC (1991b) Gram-negative sepsis. Background, clinical features and intervention. Chest 100:802-808.
3. Brandtzaeg P, Bjerre A, vstebo R, Brusletto B, Joo GB, and Kierulf P (2001) Neisseria meningitidis lipopolysaccharides in human pathology. J Endotoxin Res 7:401-420.
4. Burrell R (1994) Human responses to bacterial endotoxin. Circ Shock 43:137-153.
5. Chow JC, Young DW, Golenbock DT, Christ WJ, and Gusovsky F (1999) Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 274:10689-10692.
6. Christ WJ, Asano O, Robidoux ALC, Perez M, Wang YA, Dubuc GR, Gavin WE, Hawkins LD, Mcguinness PD, Mullarkey MA, et al. (1995) E5531, a pure endotoxin antagonist of high potency. Science (Wash DC) 268:80-83.
7. Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, and Ferrara JL (2001) LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 107:1581-1589.
8. Diks SH, van Deventer SJ, and Peppelenbosch MP (2001) Lipopolysaccharide recognition, internalisation, signalling and other cellular effects. J Endotoxin Res 7:335-348.
9. Fiuza C and Suffredini AF (2001) Human models of innate immunity: local and systemic inflammatory responses. J Endotoxin Res 7:385-388.
10. Galanos C, Hansen-Hagge T, Lehmann V, and Luderitz O (1985a) Comparison of the capacity of two lipid A precursor molecules to express the local Shwartzman phenomenon. Infect Immun 48:355-358.
11. Galanos C, Luderitz O, Rietschel ET, Westphal O, Brade H, Brade L, Freudenberg M, Schade U, Imoto M, Yoshimura H, et al. (1985b) Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem 148:1-5.
12. Gardiner KR, Halliday MI, Barclay GR, Milne L, Brown D, Stephens S, Maxwell RJ, and Rowlands BJ (1995) Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 36:897-901.
13. Hailman E, Albers JJ, Wolfbauer G, Tu AY, and Wright SD (1996) Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. J Biol Chem 271:12172-12178.
14. Hawkins LD, Ishizaka ST, McGuinness P, Zhang H, Gavin W, DeCosta B, Meng Z, Yang H, Mullarkey M, Young DW, et al. (2002) A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action and adjuvant activity. J Pharmacol Exp Ther 300:655-661.
15. Heine H, Schromm A, Zahringer U, Rossignol D, Lein E, Golenbock D, Dieter Flad H, and Ulmer A (2000) Peptidoglycan-induced TLR-2-dependent NF-κB translocation in CHO cells can not be blocked by LPS antagonists. J Endotoxin Res 6:139.
16. Kawata T, Bristol JR, Rose JR, Rossignol DP, Christ WJ, Asano O, Dubuc GR, Gavin WE, Hawkins LD, Kishi Y, et al. (1995) Anti-endotoxin activity of a novel synthetic lipid A analog. Prog Clin Biol Res 392:499-509.
17. Kobayashi S, Kawata T, Kimura A, Miyamoto K, Katayama K, Yamatsu I, Rossignol DP, Christ WJ, and Kishi Y (1998) Suppression of murine endotoxin response by E5531, a novel synthetic lipid A antagonist. Antimicrob Agents Chemother 42: 2824-2829.
18. Lau LL, Halliday MI, Lee B, Hannon RJ, Gardiner KR, and Soong CV (2000) Intestinal manipulation during elective aortic aneurysm surgery leads to portal endotoxaemia and mucosal barrier dysfunction. Eur J Vasc Endovasc Surg 19: 619-624.
19. LeMay DR, LeMay LG, Kluger MJ, and D'Alecy LG (1990) Plasma profiles of IL-6 and TNF with fever-inducing doses of lipopolysaccharide in dogs. Am J Physiol 259:R126-R132.
20. Lien E, Chow JC, Hawkins LD, McGuiness PD, Gusovsky F, and Golenbock DT (2000) A novel acyclic lipid A-like agonist activates cells via the lipopolysaccharide signaling pathway. J Endotoxin Res 6:104.
21. Lynn M, Rossignal DP, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, Vargas R, D'Angelo T, Gotzkowsky S, and McMahon FG (2003) E5564 blocks responses to endotoxin in normal volunteers with experimental endotoxemia. J Infect Dis, in press.
22. Martinez-Pellus AE, Merino P, Bru M, Conejero R, Seller G, Munoz C, Fuentes T, Gonzalez G, and Alvarez B (1993) Can selective digestive decontamination avoid the endotoxemia and cytokine activation promoted by cardiopulmonary bypass? [see comments]. Crit Care Med 21:1684-1691.
23. Morrison DC (1998) Antibiotic-mediated release of endotoxin and the pathogenesis of Gram-negative sepsis. Prog Clin Biol Res 397:199-207.
24. Norimatsu M and Morrison DC (1998) Correlation of antibiotic-induced endotoxin release and cytokine production in Escherichia coli-inoculated mouse whole blood ex vivo. J Infect Dis 177:1302-1307.
25. Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP, and Lemke JH (1999) Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 180:1584-1589.
26. Reid RR, Prodeus AP, Khan W, Hsu T, Rosen FS, and Carroll MC (1997) Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. J Immunol 159:970-975.
27. Rose JR, Christ WJ, Bristol JR, Kawata T, and Rossignol DP (1995) Agonistic and antagonistic activities of bacterially derived Rhodobacter sphaeroides lipid A: comparison with activities of synthetic material of the proposed structure and analogs. Infect Immun 63:833-839.
28. Rose JR, Mullarkey MA, Christ WJ, Hawkins LD, Lynn M, Kishi Y, Wasan KM, Peteherych K, and Rossignol DP (2000) Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins. Antimicrob Agents Chemother 44:504-510.
29. Rossignol DP, Christ WJ, Hawkins LD, Kobayashi S, Kawata T, Lynn M, Yamatsu I, and Kishi Y (1999) Synthetic endotoxin antagonists, in Endotoxin in Health and Disease (Morrison D ed) pp 699-717, Marcel Dekker Inc., New York.
30. Roumen RM, Frieling JT, van Tits HW, van der Vliet JA, and Goris RJ (1993) Endotoxemia after major vascular operations. J Vasc Surg 18:853-857.
31. Segrest J and Albers J eds (1986) Comparative Analysis of Mammalian Plasma Lipoproteins in Methods of Enzymology. Academic Press, New York.
32. Suffredini AF and O'Grady NP (1999) Pathophysiological responses to endotoxin in humans, in Endotoxin in Health and Disease (Morrison D ed) pp 817-830, Marcel Dekker Inc., New York.
33. Takada H and Kotani S (1989) Structural requirements of lipid A for endotoxicity and other biological activities. Crit Rev Microbiol 16:477-523.
34. Ulevitch RJ and Tobias PS (1995) Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 13:437-457.
35. Vreugdenhil AC, Snoek AM, van't Veer C, Greve JW, and Buurman WA (2001) LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. J Clin Invest 107:225-234.
36. Wasan KM, Strobel FW, Parrott SC, Lynn M, Christ WJ, Hawkins LD, and Rossignol DP (1999) Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels. Antimicrob Agents Chemother 43:2562-2564.
37. Wurfel MM, Hailman E, and Wright SD (1995) Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 181:1743-1754.
38. Wurfel MM and Wright SD (1995) Lipopolysaccharide (LPS) binding protein catalyzes binding of LPS to lipoproteins. Prog Clin Biol Res 392:287-295.
39. Yang H, Young DW, Gusovsky F, and Chow JC (2000) Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4. MD-2 is required for activation of mitogen-activated protein kinases and Elk-1. J Biol Chem 275:20861-20866.
40. Yin M, Bradford BU, Wheeler MD, Uesugi T, Froh M, Goyert SM, and Thurman RG (2001) Reduced early alcohol-induced liver injury in CD14-deficient mice. J Immunol 166:4737-4742.